New era for treatment in differentiated thyroid cancer

Lancet. 2014 Jul 26;384(9940):286-8. doi: 10.1016/S0140-6736(14)60663-2. Epub 2014 Apr 24.

Authors

Sigurdis Haraldsdottir¹, Manisha H Shah²

Affiliations

¹ Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
² Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Electronic address: manisha.shah@osumc.edu.

PMID: 24768111
DOI: 10.1016/S0140-6736(14)60663-2

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Agents / therapeutic use*
Female
Humans
Male
Niacinamide / analogs & derivatives*
Niacinamide / therapeutic use
Phenylurea Compounds / therapeutic use*
Sorafenib
Thyroid Neoplasms / drug therapy*

Substances

Antineoplastic Agents
Phenylurea Compounds
Niacinamide
Sorafenib